LRMR
Larimar Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 27 ▲ Four insiders at Larimar Therapeutics collectively purchased $6.07 m…
- Feb 27 ▲ 4 insiders buy $25.6M at $5.00
- May 14 ▲ Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/shar…
- May 14 ▲ Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consens…
- May 27 JP Morgan initiates
- Jun 29 FDA: Larimar Therapeutics Reports Positive Open Label Data and…
- Jul 6 ▲ 1 insider buy $166.9K at $3.34
- Sep 29 Leadership: Larimar Therapeutics Strengthens Executive Leadership with…
- Oct 30 ▲ Short interest falls 28.1% to 10.54M
- Nov 5 FDA: Larimar Therapeutics Announces Three Poster Presentations…
- Nov 9 ▲ Larimar Therapeutics completed its rolling BLA submission to the FDA…
- Nov 11 to Nov 12 ▲ 2 days of insider buys: $382.1K by 7 insiders, avg $2.71
- Nov 16 New report: subscribers see the details Unlock
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
9 insiders bought $26.1M at an average $4.92. No open-market sales. Price is 39% below their cost.
- InstitutionsBEARISH
Q3 2026: 13 added (0 new), 21 trimmed or exited.
- Short sellersCOVERING
Short interest −28.1% to 10.54M shares. 8.3 days to cover, ≈10.1% of shares.
- TrendUPTREND
3% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $691.4K |
| MORGAN STANLEY | DOUBLED | $683.7K |
| FEDERATED HERMES, INC. | DOUBLED | $604.1K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $588.0K |
| Creative Planning | ADD | $564.5K |
| Nuveen, LLC | NEAR_EXIT | $449.8K |
| IEQ CAPITAL, LLC | TRIM | $373.0K |
| Mariner, LLC | TRIM | $236.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026| Date | Firm | Rating |
|---|---|---|
| Aug 5, 2026 | Wedbush MAINTAIN | Outperform |
| Jun 30, 2026 | Baird MAINTAIN | Outperform |
| May 27, 2026 | JP Morgan INITIATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Hamilton Thomas Edward Director Nov 12, 2026 | BUY | $187.1K |
Truitt Joseph Director Nov 11, 2026 | BUY | $9.8K |
Shankar Gopi Chief Development Officer Nov 11, 2026 | BUY | $13.5K |
Celano Michael Chief Financial Officer Nov 11, 2026 | BUY | $50.0K |
Harlow John B. Jr. President and COO Nov 11, 2026 | BUY | $49.9K |
THOMAS FRANK E Director Nov 11, 2026 | BUY | $21.8K |
BEN-MAIMON CAROLE President and CEO Nov 11, 2026 | BUY | $50.0K |
Harlow John B. Jr. President and COO Sep 29, 2026 | AWARD | 800,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 3 press releases · 7 bullish · 1 bearish · 2 neutral- NEUTRAL SC 13GNov 16, 2026
RTW Investments, LP disclosed a 5.6% passive stake in Larimar Therapeutics as of September 30, 2026, representing 5,820,891 shares. This is a new 13G filing (not an amendment) by RTW, a healthcare-focused investment firm, indicating a material passive position in the clinical-stage biotech.
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS-RELEASENov 16, 2026
Larimar Therapeutics completed its rolling BLA submission seeking accelerated approval of nomlabofusp for Friedreich's ataxia, a major regulatory milestone for a clinical-stage biotech. The company reported a Q3 2026 net loss of $31.1M ($0.29 per share), narrower than the $47.7M loss a year ago…
🔒 Fresh report (last 24h), subscribers only
- BULLISH CLUSTERNov 12, 2026
Multiple Larimar Therapeutics insiders, including the CEO, CFO, President/COO, and directors, made…
Insider buying after a BLA submission is a positive signal, but the dollar amounts are modest relative to market cap. Watch for FDA acceptance of the BLA and any PDUFA date announcement as the next…
- BULLISH 8-KNov 9, 2026
Larimar Therapeutics completed its rolling BLA submission to the FDA seeking accelerated approval…
The BLA submission is a binary catalyst event. Watch for FDA acceptance for filing in early 2027 and the open label study safety update in Q1 2027. The cash runway into late Q2 2027 covers the…
All LRMR filing & press-release reports (13)
- SC 13G reportNov 16, 2026
- PRESS-RELEASE reportNov 16, 2026
- CLUSTER reportNov 12, 2026
- 8-K reportNov 9, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportSep 29, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 27, 2026
- 8-K reportFeb 27, 2026